You are here » Home » Companies » Company Overview » Aarti Drugs Ltd

Aarti Drugs Ltd.

BSE: 524348 Sector: Health care
NSE: AARTIDRUGS ISIN Code: INE767A01016
BSE LIVE 15:40 | 09 Dec 655.35 2.75
(0.42%)
OPEN

655.00

HIGH

665.00

LOW

650.00

NSE LIVE 15:31 | 09 Dec 659.65 6.45
(0.99%)
OPEN

654.40

HIGH

665.00

LOW

644.00

OPEN 655.00
PREVIOUS CLOSE 652.60
VOLUME 1212
52-Week high 684.00
52-Week low 431.10
P/E 20.44
Mkt Cap.(Rs cr) 1587.26
Buy Price 660.00
Buy Qty 99.00
Sell Price 0.00
Sell Qty 0.00
OPEN 655.00
CLOSE 652.60
VOLUME 1212
52-Week high 684.00
52-Week low 431.10
P/E 20.44
Mkt Cap.(Rs cr) 1587.26
Buy Price 660.00
Buy Qty 99.00
Sell Price 0.00
Sell Qty 0.00

Aarti Drugs Ltd. (AARTIDRUGS) - Chairman Speech

Company chairman speech

AARTI DRUGS LIMITED ANNUAL REPORT 2003-2004 CHAIRMAN'S REPORT Dear Shareholders, Aarti Drugs Limited was promoted in September, 1984 by a group of technocrat During the current year. the Company is heading to complete two decades of its existence with achievements of several milestones. I would like to record the Company's achievements so far to congratulate the Company's dedicated management team, executives, staff and workers at all levels which have made this possible. I am sure this would certainly inspire us for much bigger pursuits by unleashing oil inherent potentials inclucated in our work culture, capabilities. confidence and creditability with Customers, commitment to constant growth and desire to reach new horizons. 1. Sales : year 2003-2004, the Company has achieved highest ever Sales of more than Rs.237 crores. 2. Dividend : For the year 2003-2004, the Company has declared/recommended highest ever Total Dividend of Rs.3 (30%) per share. 3. Shares Liquidity: During the year 2003-2004, the Company's Shares also got listed on the National Stock Exchange in addition to listing on The Stock Exchange Mumbai and Ahmedabad Stock Exchange. 4. Market Leadership : Over the years, the Company has been able to carve a niche for itself by establishing its strong presence in the anti-diarrhea, anti inflammatory therapeutic groups with products like tinidazole, metronidazole, secnidazole. diclofenac sodium, ranitidine hcl, nimesulide, rofecoxib, etc. Due to changge in disease profile in India from diseases related to poor higenic conditions to life style diseases, the Company has focused its attention on the Cardio Vascular. Anti-diabetic, Anti- depression, Anti-biotic therapeutic groups with the products like Ticlopidine, Clopidogrel, Rofecoxib Valdecoxib, Ciprofloxacin etc. The Company, in fact, enjoys market leadership in eight out of its fifteen principal product. The Company's commitment to customer service in terms quality and timely delivery was marked by the Best Vendor Award 2000-2001 from Organisation of Pharmaceutical Producers of India (OPPI). 5. Large Customer base: Domestically, the Company has been supplier to well known pharmaceutical companies in India which includes Pfizer, Glaxo, Merck, Knoll Pharmaceuticals, Sandoz, Ranbaxy, Dr. Reddy's Laboratories, Cipla, Sun pharmaceuticals. Cadila Group, Ipca Laboratories, Nicholas Piramal, Hindustan Lever, Estle. Colour Chem, and so on. Internationally, the Company exports its products to about 65 countries spread across continents, namely, Australia, Africa, Asia, Europe, Latin America, and North America. 6. Strong Technicals and wide range of products: With the core promoters/ management including technocrats, the Company has been very strong on technical side which is reflected in its ability to develop and manufacture wide range of products in a cost effective manner by regularly evaluating alternate processes, inputs, sources etc. Strong technical side has also helped the Company to continuously update and upgrade its technology and improvement in processes, increased yields and value additions as also to foresee opportunities in new products and adjust to the dynamics of the market. Wide range of products enables the Company to balance seasonal and cyclical fluctuations in the market. 7. Bigger multi-locational flexible Plant Capacities: The Company has built its plant capacities keeping in mind future opportunities. The Company is way ahead of its competitors in terms of plant capacities which has helped to cater to higher demand, increase its market share, economies in production costs and maintain steady growth. Further, multi-locational facilities and workforces dedicated to various products have flexibility of being put to alternate use to meet the demand. 8. Export House Status : Time and again, the Company has achieved merits in export performances which is marked by Certificates of Merits from Chemexcil in the year 1989-90, 1991-92 and 2000-01. The Company has been awarded Government Recognised Export House status from 1996. 9. Research & Development facility: The Company's Research & Development facility at Plot Nos. N-198 and G-60, MIDC, Tarapur, Boisar, Tal. Palghar, Dist. Thane, Maharashtra are approved by Department of Scientific & Industrial Research (DSIR), Government of India which has constantly strived to improve processes, product yields and new products. 10. Dedicated workforce : Last, but not the least, 675 strong dedicated workforce has been the catalyst for the Company's achievements. In the past, as a strategy for growth and consolidation, the Company has always expanded its plant facilities by new project implementations, acquisitions and amalgamations which were by and large financed from internal cash accruals. Now with the built up of relatively stronger net worth, the Company is in a position to consider and exploit bigger opportunities by taking a bigger leap towards sustained growth. With the liberalized economic environment and increasing globalisation, the years ahead are expected to throw several challenges and opportunities pre- and-post the introduction of the WTO Protocol in 2005. I am sure with the strong inherent capabilities/resource base, dynamic management, dedicated workforce and a vision to be India's leading manufacturer of bulk drugs and high value Active Pharma Intermediates (APIs), the Company is poised to unleash its true potentials to meet the challenges and exploit the growth opportunities ahead in the best interest of our shareholders and stakeholders. With your continued support and patronage, I am sure We will be able to scale newer heights and milestones of success and prosperity in the years ahead. Thank you and with best regards, Sincerely Yours, C.V. Gogri Chairman

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard